Aptevo Therapeutics Inc. (APVO) key performance indicators and operating metrics (1 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Percent of Evaluable Patients Achieving Remission with Mipletamig Combination Therapy for Frontline Acute Myeloid Leukemia | 81.00 percent | FY2026-Q1 |
Back to APVO overview · APVO earnings · APVO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.